Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Dossier "AIDS"

Inhibitory effect of the oral immune response modifier, bestatin, on cell-mediated and cell-free HIV infection in vitro

AS Bourinbaiar\(^1\), S Lee-Huang\(^1\), K Krasinski\(^2\), W Borkowsky\(^2\)

\(^1\)Department of Biochemistry and \(^2\)Department of Pediatrics, Division of Infectious Diseases, New York University Medical Center, 550 First Avenue, New York, NY 10016, USA

Summary - The antiviral effect of the immunomodulating anti-cancer agent, bestatin, was examined in vitro by exposing MT-4 lymphocytes to HIV in the presence of 10-fold dilutions of drug (range 100 \(\mu\)g/ml – 100 pg/ml). The reduction in infectivity was measured by \(\beta\)-24 ELISA and compared to the effect of established anti-HIV drugs – azidothymidine (AZT) and dextran sulfate. The results indicate that low doses of bestatin (1 \(\mu\)g/ml) can completely inhibit viral infection resulting either from inoculation with free virus or coculture with infected lymphocytes. Unlike AZT or dextran sulfate, bestatin prevents HIV infection without interfering with the rate of cell growth. No appreciable decrease in HIV production was observed when chronically infected virus-producing T cell lines \(\text{ie, H9, MOLT-4, HPB-ALL, 8E5 and MT-2}\) were treated with bestatin. Bestatin appears to act in the early stages of viral penetration, possibly through inhibition of lymphocyte-associated aminopeptidases.

bestatin / HIV / T lymphocytes

Introduction

Bestatin, a low molecular weight dipeptide (2S, 3R)-3-amino-2-hydroxy-4-phenylbutanoyl-L-leucine, is an orally active biological response modifier derived from a microbial source (Streptomyces olivoreticuli) and is known as an inhibitor of exopeptidases such as leucine aminopeptidase and aminopeptidase B, found mostly on the membrane of human lymphocytes and monocytes \([1, 2]\). We recently reported \([3, 4]\) that coumarin-derived compounds, also major inhibitors of aminopeptidases \([5]\) and serine proteases \([6]\), display anti-HIV activity \textit{in vitro} possibly through inhibition of hydrolases on the surface of lymphocytes.

Bestatin was discovered by Umezawa in 1976 \([1]\) and has been successfully used since for the treatment of certain forms of leukemias and solid tumors \([7, 8]\). Mathé et al \([9, 10]\) reported immunoregulatory action of bestatin in immunocompromised cancer patients and in individuals infected with human immunodeficiency virus (HIV). However, recent clinical trials conducted in Denmark \([11]\) concluded that no significant difference was observed between immunological parameters of HIV-positive patients treated with bestatin and patients on placebo. Because of the discrepancy between these clinical studies and the absence of any reported data on antiretroviral activity of aminopeptidase inhibitors, we investigated whether bestatin has a direct effect on HIV infection \textit{in vitro}.

Materials and Methods

Infection assay using free virus

To determine whether bestatin may affect HIV infectivity in the virus-target cell system, filtered (pore size, 0.22 \(\mu\)m) culture medium from HIV-producing H9 line (infected with IIIB strain of HIV-1) titrated to 100 ng/ml of p24 gag protein or an equivalent of \(10^9\) viral particles per ml was used as a viral inoculum. Since only one out of a hundred released particles is infectious, 100 ng of p24 would in fact correspond to \(10^4\) infectious viruses per ml. The rationale and methodology for these calculations have been described earlier \([12-14]\). Target MT-4 lymphocytes \((10^5\) cells/ml\) were exposed to 10-fold dilutions of drug (from 100 \(\mu\)g/ml to 100 pg/ml) immediately followed by the addition of virus, and were cultured in 96-well plates (200 \(\mu\)l of culture medium/well) for 1 hour. Each dose was tested in triplicate.
in four separate experiments. Inoculated cells were then washed and subcultured for 4 days at 37°C in 5% CO₂ until signs of infection, ie, syncytial cells in untreated control wells were observed under microscope. Productivity of infection was then tested by p24 ELISA. The antiviral effect of bestatin (Mₙ 345) was compared to the effect of established anti-HIV drugs ie, dextran sulfate (Mₙ 8000; range 100 μg-100 pg per ml) and AZT (Mₙ 267; range 10⁻³-10⁻⁹ M). All drugs were purchased from Sigma, St Louis, MO.

**Infection assay in cell-cell system**

HIV-1 producing unstimulated HPB-ALL T lymphocytes were incubated at a ratio of 1:10 with uninfected MT-4 lymphocytes (10⁶ cells/ml) in the continuous presence of log₁₀ dilutions of bestatin or two control drugs, AZT and dextran sulfate. Upon appearance of syncytial cells at 2 days post-infection, the coculture medium was tested for viral production by measuring the release of HIV-1 core protein p24 by ELISA. Spontaneous release of virus in control wells containing HIV-infected HPB-ALL alone was subtracted from experimental values.

**Effect of drugs on HIV synthesis from persistently infected T cell lines**

HIV-1 producing H9, MOLT-4, HPB-ALL, 8E5, and MT-2 T lymphocytes (10⁶ cells/ml) were grown in 96-well Multiscreen filtration plates with gravity-permeable bottom (Millipore, Bedford, MA) in the presence of various concentrations of drugs for 3 days. In order to fit into the detection range of p24 ELISA (c. 10 ng-10 pg of gag antigen per ml) the samples of culture medium were appropriately diluted and added to a 96-well ELISA plate. All cultures were maintained in RPMI 1640 culture medium with 10% FBS, L-glutamine, penicillin, and streptomycin in 5% CO₂ atmosphere.

**Determination of viral production by ELISA**

The dose-response to drugs was quantitated by measuring the amount of cell-free p24 antigen in culture supernatants of infected cells according to the manufacturer’s (HIV core p24 gag antigen ELISA kit, Coulter, Hialeah, FL). The amount of released p24 was calculated by comparing to the optical density of supplied p24 standards. The lower limit of reliable sensitivity of this kit was set at 10 pg/ml or p24.

**Toxicity assay**

MT-4 cells and HIV-infected H9, MOLT-4, HPB-ALL, and MT-2 lymphocytes were grown in the presence or absence of log₁₀ dilutions of bestatin, AZT, or dextran sulfate. The cells were pulsed for 4 h with 0.5 μCi/ml of [³H] thymidine (Amersham, Arlington Heights, IL). The incorporation of the labeled DNA precursor was determined by scintillation spectroscopy and compared to the cpm values of the control cells cultured without drugs.

**Results**

To determine whether bestatin may affect the infectivity of HIV, we evaluated its effect in infection assays in which target MT-4 cells were exposed either to cell-free HIV (fig 1a) or HIV-infected HPB-ALL T lymphocytes (fig 1b). The inhibitory effect of bestatin was compared to the antiviral action of previously reported compounds with anti-HIV activity-dextran sulfate [15] and AZT [16]. All three drugs demonstrated an inhibitory capacity. Viral infection was completely abrogated at a microgram concentration of bestatin. Although infectious doses used in two types of assays were titrated to achieve the same level of viral production in MT-4 (c. 40 ng/ml of p24 in untreated controls), it appears that AZT and dextran sulfate exhibit lower antiviral activity against cell-mediated infection. Unlike bestatin which remained active at a dose of 1 μg/ml, there was approximately one log₁₀ drop in drug potency when AZT and dextran sulfate were tested in cell-cell systems using HPB-ALL cells as the HIV donor. The end-point antiviral concentrations attained by these drugs are shown in figures 1a and 1b.

To determine whether observed inhibition in viral production was not related to the growth suppression of host cells, we examined the effect of drugs on incorporation of isotope-labeled thymidine. As opposed to AZT, bestatin-caused reduction in p24 production from HIV-exposed MT-4 lymphocytes was not correlated to the inhibition of cell growth. Surprisingly, the treatment with dextran sulfate was associated with an increase in [³H] TdR uptake (fig 2). Similar effects were observed when HIV-infected T cell lines (H9, MOLT-4, HPB-ALL, 8E5, and MT-2) were treated with these drugs and then tested for thymidine uptake (data not shown).

We then tested the effect of bestatin on viral synthesis in established T cell lines which spontaneously produced various levels of p24 (range 40 ng-0.2 ng of p24 per ml). Five cell lines routinely maintained in our laboratory, H9, MOLT-4, HPB-ALL, 8E5, and MT-2, were washed and then grown in triplicate in a 96-well plate in the presence of various concentrations of antiviral compounds for 3 days. Following initial titration, appropriately diluted culture supernatants were added into a 96-well ELISA plate and tested for p24 production. The representative dose-response to bestatin and AZT treatment is illustrated in figures 3a and 3b. Although a limited decrease in viral production was observed for
some of the cell lines, no reduction in p24 release comparable to the effect shown in figure 1 was observed at any time.

Discussion

Bestatin displays anti-HIV as demonstrated by reduction in productive viral infection in MT-4 lymphocytes. Complete inhibition of viral infection resulting from exposure to free HIV or infected cells was achieved by doses of bestatin starting from as low as 1 µg/ml. The highest (100 µg/ml) concentration of bestatin employed in our study did not show any appreciable inhibition of [3H]thymidine uptake by MT-4, suggesting that antiviral activity was specific and not related to the suppression of cell proliferation. We have also carried out a set of experiments using one primary HIV-1 isolate and PHA-stimulated peripheral lymphocytes as target cells. The concentration of bestatin required to inhibit de novo HIV infection in this situation was the same as with the laboratory strain of HIV. Since we have not yet tested a larger number of primary isolates, these results were not included in this study.

Earlier in vitro screenings demonstrated that proliferation of some but not all leukemic cell lines was inhibited only in the presence of extremely high doses of bestatin (4.5 mg/ml). No negative effect was observed after exposure to 450 µg of bestatin [17]. Usual pharmacological doses of bestatin prescribed for oral administration do not exceed 30–60 mg per day [7, 8]. This dosage is at least 10-fold lower than for AZT—routinely administered at doses equal to 500 mg/day or higher and causes serious adverse effects such as myelosuppression and inability to tolerate the drug. The antiviral effect of AZT was associated in a dose-dependent manner with significant growth-suppressive activity and cell death was observed at a millimolar concentration or an equivalent of 267 µg/ml. Interestingly, antivirally active concentrations of dextran sulfate appeared to have an opposite effect to AZT, ie, increased proliferation of target MT-4 cells. Al-

Fig 1. Effect of bestatin, dextran sulfate, and AZT in blocking de novo HIV infection in MT-4 lymphocytes (note that concentrations for AZT are in log10 molar increments starting from 10^{-5} M or 267 µg/ml). The experiments using free virus (a) or infected HPB-ALL lymphocytes co-cultured with MT-4 (b) were repeated at least four times and typical results reflecting the decrease of p24 release at 4 (a) and 2 (b) days post-infection are shown. The complete inhibition of infection in either types of antiviral assays is observed at 1 µg/ml for bestatin. In experiments with free HIV, starting concentrations of drugs are 10-fold lower than in chart (b). Decrease in drug potency is observed for AZT and dextran sulfate when tested against cell-to-cell HIV spread.
Fig 2. Effect of bestatin, dextran sulfate, and AZT on proliferation of MT-4 lymphocytes as measured by [%H]Tdr incorporation assay. Results indicate that reduction in p24 production from HIV-infected lymphocytes is not correlated to cell growth pattern as there is no observable dose-effect for bestatin. Antivirally active doses of AZT and dextran sulfate caused inhibition and activation of proliferation respectively.

though dextran sulfate has been known for two decades to be an activator of polyclonal B-cell proliferation [18], it has also been reported as mitogenic to normal T lymphocytes [19]. To our knowledge, induction of proliferation of human T lymphocytic lines by this polysaccharide anticoagulant has never been reported before. It is conceivable that this phenomenon can be related to the results of the recent clinical trial showing the increase of plasma viremia in patients treated with dextran sulfate [20]. It cannot be ruled out that such an unfavorable effect results from the reactivation of resting T lymphocytes harboring HIV and subsequent upregulation of retroviral expression. It appears that in vitro treatment with AZT and dextran sulfate causes two opposite extremes in the cell replication process, suppression and activation of proliferation. Presumably, neither of these effects can be of a neutral nature without provoking undesirable side-effects in the human body. In contrast, pharmacological doses of bestatin do not cause any detectable effect on proliferation of MT-4 cell lines. Moreover, bestatin has been reported to have a beneficial effect by enhancing the growth of bone marrow stem cells [21, 22] and elevating the number of T cell precursors which are committed to differentiate into CD4+ cells [23].

In an infection assay with free virus, antiviral drugs were present during the brief period of inoculation and productivity of infection was tested 4 days later by ELISA. This type of assay was primarily aimed at demonstrating the effect of the drug on earlier stages of the viral life cycle, ie, adsorption and penetration. On the other hand, in already infected virus-producing cell lines, viral integration is already completed and, thus, the expression of proviral genome and assembly of viral particles are independent from the initial events. The experiment aimed at revealing the effect of bestatin on post-translational expression of HIV in steady producing T cell lines, were intended to identify different mechanism(s) of action of the drug—undetectable under conditions of the infectivity assay described above. In these experiments, however, we were unable to identify an effect which could have been interpreted as independent from the negative effect on cell growth. Thus, it appears that bestatin may act preferentially in the initial steps of viral replication, suggesting that this drug would be useful in blocking de novo infection resulting from exposure to free virions or cell-associated HIV. Unfortunately, as clinical experience with AZT has already shown, this effect may be of limited benefit in a situation in which viral infection is already established and progressed beyond an irreversible point.

The polysaccharide anticoagulant, dextran sulfate, is known to inhibit the adherence of HIV to the surface of target cells [15] and its antivirally active concentrations are comparable to bestatin. Although the mechanism of dextran sulfate action remains a subject of controversy, it has been proposed that this compound may act by inhibiting the binding of the viral gp120 envelope glycoprotein to the CD4 molecule which serves as a viral receptor on the surface of permissive cells [24]. Mathé et al proposed that the target of bestatin is also the CD4 [7, 9, 10]. This possibility has been supported by Sakurada et al [17], who established that the cell-aggregating action of bestatin was counteracted by pre-treatment with the CD4 antibody but not by antibodies against LFA1, CD11a, CD11b, CD11c, or CD18. Although the elucidation of the role of CD4 may be worthy of exploration, it is unlikely that such a mechanism
of action can provide an exclusive explanation for the observed biological effect. Both drugs, dextran sulfate and bestatin, were capable of preventing HIV infection when CD4-negative placental trophoblasts were used as target cells [25, Bourinbaiar et al, in preparation).

Current opinion on the antiviral effect of hydrolase inhibitors is based on experimental evidence indicating that binding capacity and infectivity of viruses depends on the cleavage of envelope glycoproteins upon entry into the target cell [26]. This cleavage is believed to assure functional activation of retroviral fusion proteins and presumably occurs either before entry of the virus into the cell or in the endosomal compartment [27]. A wide range of membrane-bound host enzymes, including serine [6, 26-31], aspartic [32], and cysteine proteases [33] were implicated in this process. Recent discovery of the involvement of furin, a subtilisin-type human endoprotease, in the cleavage of HIV-1 envelope gp160 glycoprotein and inhibition of HIV infection by peptidyl-chloromethylketones may indicate the target to intervention [4, 34]. However, as opposed to serine proteases which belong to the endopeptidase class of hydrolases, aminopeptidases act primarily as exopeptidases, catalyzing the hydrolysis of N-terminal amino acid residues from the oligopeptides, and have never been reported to be involved in the HIV infection process. Thus, the mechanism of anti-HIV action of bestatin may be different from that reported for serine proteases. Alternatively, it is possible that inhibition of HIV infection by bestatin conforms to a general bioisosteric mechanism. Both types of lymphocyte ectoenzymes, trypsin-like proteases and aminopeptidases, can be inhibited by ketone-containing peptides [36] as well as by coumarin-based suicide substrates [5]-compounds which have been shown by us to display anti-HIV activity [3, 4]. It is likely that bestatin acts by regulating peptidases on the surface and/or cytosol of host lymphocytes [2, 7, 8], but at present only a few of them have been characterized [2, 35-40], eg, aminopeptidase N. We are now working in this direction in order to identify which one could be the most crucial for viral infectivity. It has recently been reported that aminopeptidase

![Graph](image-url)
N on the surface of epithelial cells serve as the receptor for coronaviruses—responsible for respiratory infections [41-42]. Prevention of HIV infection by bestatin, a specific inhibitor of aminopeptidases [43-45], supports the hypothesis regarding the existence of alternative HIV receptor(s) [28, 30] and modes of viral spread [46], rationalizing the paradox of the permissiveness of CD4-negative cells, eg, epithelial cells to HIV [47]. Bestatin is known as a potent orally active immunomodulator and has been successfully used for adjuvant immunotherapy of malignant diseases [7, 8] as well as an enhancer of host resistance to opportunistic infections [48]. Bestatin has been reported to improve the survival rate in immunosuppressed mice infected with Candida albicans – a frequently found fungal infection in patients with HIV [49]. In view of the demonstrated effect against HIV in vitro, bestatin should be considered for re-examination in extended clinical trials and its therapeutic value must be verified by detailed analysis of immunological as well as virological parameters.

Acknowledgments

We thank CF Coleman and EC Fruhstorfer for editorial assistance. This work was supported in part by grants from the NIH T32 AI07382, RO1 AI31343, RO1 DA04791, RO1 HD26613, and a grant from Schubert Foundation.

References

1 Umezawa H. Aoyagi T. Activities of proteinase inhibitors of microbial origin. In: Barrett AJ, ed. Proteinases in Mammalian Cells and Tissues. Amsterdam: Elsevier/North Holland Biomedical Press: Amsterdam 1977; p 637
2 Aoyagi T. Suda H. Nagai M. Ogawa K. Suzuki J. Takeuchi T. Umezawa H. Aminopeptidase activities on the surface of mammalian cells. Biochim Biophys Acta 1976;452:131
3 Bourinbaiar AS. Tan X. Nagorny R. Effect of the oral anticoagulant, warfarin, on HIV-1 replication and spread. AIDS 1993;7,129
4 Bourinbaiar AS. Tan X. Nagorny R. Inhibitory effect of coumarins on HIV replication and cell-mediated or cell-free viral infection. Acta Virol 1993;37:241
5 Kanaoka Y. Takahashi T. Nakayama H. A new fluorogenic substrate for aminopeptidases Chem Pharm Bull 1977; 25:3126
6 Zimmermann M. Yurevicz E. Patel G. A new fluorogenic substrate for chymotrypsin. Anal Biochem 1976;70:258
7 Mathé G. Bestatin, an aminopeptidase inhibitor with a multi-pharmacological function. Biomed & Pharmacother 1991;45:49
8 Ota K. Uzuaka Y. Clinical trials of bestatin for leukemia and solid tumors. Biotherapy 1992;4:205
9 Mathé G. Umezawa H. Misset JL. Bienza S. Canon C. Misset M. Reizenstein P. Immunomodulating properties of bestatin in cancer patients. A phase II trial. Biomed & Pharmacother 1986;40:379
10 Mathé G. Blaszek I. Cazac N. Delgado M. Misset JL. From experimental to clinical attempts in immunorestoration with bestatin and zinc. Comp Immunol Microbiol Infect Dis 1986;9:241
11 Hording M. Gotsche PC. Duhl Christiansen L. Byggbjer IC. Faber V. Double-blind trial of bestatin in HIV-positive patients Biomed & Pharmacother 1990;44:475
12 Bourinbaiar AS. HIV and gag. Nature 1991;349:111
13 Bourinbaiar AS. Weight of HIV. AIDS Res Human Retrovir 1992;8:1545
14 Bourinbaiar AS. Nagorny R. Tan X. Heaviness of HIV particles in quantum relation to infectiousness and responsiveness to interferon. In: Andrieu JM, ed. Viral Quantitation in HIV Infection 1991; Paris: John Libbey Eurotext, p 41
15 Mitsuya H. Looney DJ. Kuno S. Ueno R. Wong-Staal F. Broder S. Dextran sulfate suppression of viruses of HIV family: inhibition of virion binding to CD4+ cells. Science 1988;240:646
16 Mitsuya H. Weinhold KJ. Furman PA et al. 3'-Azido-3'-deoxylhydroxy (BW AS09U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985;82:7096
17 Sakurada K. Kimamura M. Kobayashi M et al. Inhibitory effect of bestatin on the growth of human leukemic cells. Acta Oncol 1990;29:799
18 Gronowicz E. Coutinho A. Selective triggering of B cell subpopulations by mitogens. Eur J Immunol 1974;4:771
19 Palacios R. Sugawara I. Fernandez C. Dextran-sulfate: A mitogen for human T lymphocytes. J Immunol 1982;128:621
20 Flexner C. Barditch-Crova PA. Kornhauser DM et al. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother 1991;35:2544
21 Shibuya K. Chiba S. Hino M. Kitamura T. Miyagawa K. Takaku F. Miyazano K. Enhancing effect of ubenimex (bestatin) on proliferation and differentiation of hematopoietic progenitor cells, and the suppressive effect on proliferation of leukemic cell lines via peptidase regulation. Biomed & Pharmacother 1991;45:71
22 Abe F. Matsuda A. Schneider M. Talmadge JE. Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice. Cancer Immunol Immunother 1992;32:75
23 Wakabayashi Y. Hashimoto M. Saitoh K. Otsawa H. Koike M. Hirose S. Effects of bestatin (ubenimex) on human T cell colony formation. Anti-Cancer Drugs 1991;2:39
24 Lederman S. Gulick R. Chess L. Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV. J Immunol 1989;143:1149
25 Bourinbaiar AS. Nagorny R. Association of anti-HIV 1 effect of dextran sulfate with prevention of lymphocyte-to-lymphoblast adhesion. Immunol Infect Dis 1992;2:245
26 Korant BD. Regulation of animal virus replication by protein cleavage. In: Reich E. Rifkin DB. Shaw E. eds. Proteases and Biological Control. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1975; p 621
27 Andersen KB. Cleavage fragments of the retrovirus surface protein gp70 during virus entry. J Gen Virol 1987; 68:2193
28 Hattori T, Koito A, Takatsuki K, Kido H, Katunuma N. Involvement of tryptase-related cellular protease(s) in human immunodeficiency virus type 1 infection. FEBS Lett 1989;248:48
29 McCune JM, Rabin LB, Feinberg MB, Lieberman M, Kosak JC, Reyes GR, Weissman IL. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 1988;53:55
30 Kido HA, Fukutomi N, Katunuma N. A novel membrane-bound serine esterase in human T4+ lymphocytes immunologically reactive with an antibody inhibiting syncytia induced by HIV-1: purification and characterization. J Biol Chem 1990;265:21979
31 Avril LE, di Martino-Ferrer M, Barin F, Gauthier F. Interactions between a membrane-associated serine protease of U-937 monocytes and peptides from V3 loop of the human immunodeficiency virus type 1 (HIV-1) gp120 envelope glycoprotein. FEBS Lett 1993;317:167
32 Travis BM, Dykers TI, Hewgill D, Ledbetter J, Tsu TT, Hu SL, Lewis JB. Functional roles of the V3 hypervariable region of HIV-1 gp160 in the processing of gp160 and in formation of syncytia in CD4+ cells. Virology 1992;186:313
33 Guy B, Geist M, Dott K, Spehrer D, Kieny MP, Lecocq JP. A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein. J Virol 1991;65:1325
34 Hallenberger S, Bosch V, Angliker H, Shaw E, Klein HD, Garten W. Inhibition of cleavage activation of HIV-1 glycoprotein gp160. Nature 1992;360:358
35 Amoscato AA, Alexander JW, Babcock GF. Surface aminopeptidase activity of human lymphocytes. I. Biochemical and biologic properties of intact cells. J Immunol 1989;142:1245
36 Bauvois B. Murine thymocytes possess specific cell surface-associated exoaminopeptidase activities: preferential expression by immature CD4-CD8-subpopulations. Eur J Immunol 1990;20:459
37 Ansorge S, Schon E, Kunz D. Membrane-bound peptidases of lymphocytes: functional implications. Biomed Biochem Acta 1991;50:799
38 Grdisa M, Vitale L. Types and localization of aminopeptidases in different human blood cells. Int J Biochem 1991;23:339
39 Hendriks D, De Meester I, Umiel T, Vanhoof G, van Sande M, Scharpe S, Yaron A. Aminopeptidase P and dipeptidyl peptidase IV activity in human leukocytes and in stimulated lymphocytes. Clin Chim Acta 1991;196:87
40 Kenny AJ, Turner AJ. Mammalian Ectoenzymes, Amsterdam: Elsevier, 1987
41 Yeager CL, Ashman RA, William RK. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 1992;357:420
42 Delmas B, Gelfi J, L’Haridon R, Vogel LK, Sjostrom H, Noren O, Lauze H. Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV. Nature 1992;357:417
43 Burley SK, David PR, Lipscomb WN. Leucine aminopeptidase: bestatin inhibition and a model for enzyme catalyzed peptide hydrolysis. Proc Natl Acad Sci USA 1991;88:6916
44 Taylor A, Peliti CZ, Jahngen EG Jr, Laxman E, Szewczuk Z, Torre FJ. Use of azidobestatin as photoaffinity label to identify the active site peptide of leucine aminopeptidase. Biochemistry 1992;31:4141
45 Tieku S, Hooper NM. Inhibition of aminopeptidases N, A and W. A re-evaluation of the actions of bestatin and inhibitors of angiotensin converting enzymes. Biochem Pharmacol 1992;44:1725
46 Nara P, Tsai WP, Kung HF, Minassian A, Garrity R, Goudsmit J, Rimmelzwaan G. Universal cellular tropism? Nature 1992;360:215
47 Bourinbaiar AS, Nagorny R. Inhibitory effect of natural interferon alpha on HIV transmission from epithelial cells to lymphocytes in vitro. Eur J Pharmacol 1993;230:15
48 Ishizuka M, Abe F, Abe S, Uchida K, Ikeda T, Ito N, Aoyagi K, Yamaguchi H, Takeuchi T. Enhancement of host resistance to opportunistic infections by ubenimex (bestatin). Adv Exp Med Biol 1992;319:193
49 Aoyagi K, Itoh N, Abe F. Enhancement by ubenimex (bestatin) of host resistance to Candida albicans infection. J Antibiot 1992;45:1778